| abstract |
The present invention relates to a non-neurotoxic plasminogen activator (DSPA), eg from Desmodus rotundus, or in particular to humans for the manufacture of injectable therapeutics for the therapeutic treatment of human stroke. The use of the derived genetically modified plasminogen activator. According to a preferred embodiment of the present invention, a non-toxic plasminogen activator comprising at least one component of a so-called symgene triad is used. |